

# MECHANISMS OF VASCULAR DISEASE:

A REFERENCE BOOK FOR VASCULAR SPECIALISTS



EDITED BY ROBERT FITRIDGE AND MATTHEW THOMPSON  
COMPLETELY UPDATED EDITION 2011

BARR SMITH PRESS

# Mechanisms of Vascular Disease



# Mechanisms of Vascular Disease:

## A Reference Book for Vascular Specialists

Robert Fitridge

*The University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia*

Matthew Thompson

*St George's Hospital Medical School, London, UK*



BARR SMITH PRESS

An imprint of  
The University of Adelaide Press

Published in Adelaide by

The University of Adelaide, Barr Smith Press  
Barr Smith Library  
The University of Adelaide  
South Australia 5005  
press@adelaide.edu.au  
www.adelaide.edu.au/press

The University of Adelaide Press publishes peer-reviewed scholarly works by staff via Open Access online editions and print editions.

The Barr Smith Press is an imprint of the University of Adelaide Press, reserved for scholarly works which are not available in Open Access, as well as titles of interest to the University and its associates. The Barr Smith Press logo features a woodcut of the original Barr Smith Library entrance.

© The Contributors 2011

This book is copyright. Apart from any fair dealing for the purposes of private study, research, criticism or review as permitted under the Copyright Act, no part may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission. Address all inquiries to the Director at the above address.

This CIP cataloguing for this work is as follows;

Mechanisms of vascular disease : a reference book for vascular surgeons / Robert Fitridge, Matthew Thompson, [editors].

1. Blood vessels, Diseases.
  2. Blood vessels, Surgery.
- 
- I. Fitridge, Robert
  - II. Thompson, M. M.

For the full Cataloguing-in-Publication data please contact National Library of Australia:  
cip@nla.gov.au

ISBN (paperback) 978-0-9871718-2-5

Book design: Midland Typesetters

Cover design: Emma Spoehr, based on a diagram by Dave Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre

Paperback edition printed by Griffin Press, South Australia

# Table of Contents

Contributors vii

Detailed Contents xi

1. Endothelium 1  
*Paul Kerr, Raymond Tam, Frances Plane (Calgary, Canada)*
2. Vascular smooth muscle structure and function 13  
*David Wilson (Adelaide, Australia)*
3. Atherosclerosis 25  
*Gillian Cockerill, Qingbo Xu (London, UK)*
4. Mechanisms of plaque rupture 43  
*Ian Loftus (London, UK)*
5. Current and emerging therapies in atheroprotection 79  
*Stephen Nicholls, Rishi Puri (Cleveland, USA)*
6. Molecular approaches to revascularisation in peripheral vascular disease 103  
*Greg McMahon, Mark McCarthy (Leicester, UK)*
7. Biology of restenosis and targets for intervention 115  
*Richard Kenagy (Seattle, USA)*
8. Vascular arterial haemodynamics 153  
*Michael Lawrence-Brown, Kurt Liffman, James Semmens, Ilija Sutalo (Melbourne & Perth, Australia)*
9. Physiological haemostasis 177  
*Simon McRae (Adelaide, Australia)*
10. Hypercoagulable states 189  
*Simon McRae (Adelaide, Australia)*
11. Platelets in the pathogenesis of vascular disease and their role as a therapeutic target 201  
*Sandeep Prabhu, Rahul Sharma, Karlheinz Peter (Melbourne, Australia)*
12. Pathogenesis of aortic aneurysms 227  
*Jonathan Golledge, Guo-Ping Shi, Paul Norman (Townsville & Perth, Australia; Boston, USA)*
13. Pharmacological treatment of aneurysms 247  
*Matthew Thompson, Janet Powell (London, UK)*
14. Aortic dissection and connective tissue disorders 255  
*Mark Hamilton (Adelaide, Australia)*
15. Biomarkers in vascular disease 277  
*Ian Nordon, Robert Hincliffe (London, UK)*
16. Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon 295  
*Martin Veller (Johannesburg, South Africa)*
17. SIRS, sepsis and multiorgan failure 315  
*Vishwanath Biradar, John Moran (Adelaide, Australia)*
18. Pathophysiology of reperfusion injury 331  
*Prue Cowled, Robert Fitridge (Adelaide, Australia)*
19. Compartment syndrome 351  
*Edward Choke, Robert Sayers, Matthew Bown (Leicester, UK)*
20. Pathophysiology of pain 375  
*Stephan Schug, Helen Daly, Kathryn Stannard (Perth, Australia)*

21. Postamputation pain 389  
*Stephan Schug, Gail Gillespie*  
*(Perth, Australia)*
  22. Treatment of neuropathic pain 401  
*Stephan Schug, Kathryn Stannard*  
*(Perth, Australia)*
  23. Principles of wound healing 423  
*Gregory Schultz, Gloria Chin,*  
*Lyle Moldauer, Robert Diegelmann*  
*(Florida, USA)*
  24. Pathophysiology and principles of  
varicose veins 451  
*Andrew Bradbury (Birmingham, UK)*
  25. Chronic venous insufficiency and leg  
ulceration: Principles and vascular  
biology 459  
*Michael Stacey (Perth, Australia)*
  26. Pathophysiology and principles of  
management of the diabetic foot 475  
*David Armstrong, Timothy Fisher,*  
*Brian Lepow, Matthew White,*  
*Joseph Mills (Tucson, USA)*
  27. Lymphoedema – Principles, genetics  
and pathophysiology 497  
*Matt Waltham (London, UK)*
  28. Graft materials past and future 511  
*Mital Desai, George Hamilton*  
*(London, UK)*
  29. Pathophysiology of vascular graft  
infections 537  
*Mauro Vicaretti (Sydney, Australia)*
- Index 549

# List of Contributors

David G Armstrong  
The University of Arizona  
Southern Arizona Limb Salvage Alliance  
Tucson, AZ  
USA

Vishwanath Biradar  
Intensive Care Unit  
The Queen Elizabeth Hospital  
Woodville, SA  
Australia

Matthew Bown  
Department of Vascular Surgery  
University of Leicester  
Leicester  
UK

Andrew W Bradbury  
University Department of Vascular Surgery  
Birmingham Heartlands Hospital  
Birmingham  
UK

Edward Choke  
Department of Vascular Surgery  
University of Leicester  
Leicester  
UK

Gillian Cockerill  
Department of Clinical Sciences  
St George's Hospital Medical School  
London  
UK

Prue Cowled  
Department of Surgery  
University of Adelaide  
The Queen Elizabeth Hospital  
Woodville, SA  
Australia

Helen Daly  
Royal Perth Hospital  
Perth, WA  
Australia

Mital Desai  
University Department of Vascular Surgery  
Royal Free Hospital  
University College  
London  
UK

Robert F Diegelmann  
Department of Biochemistry  
Medical College of Virginia  
Richmond, VA  
USA

Timothy K Fisher  
Rashid Centre for Diabetes and Research  
Sheikh Khalifa Hospital  
Ajmon  
UAE

Robert A Fitridge  
Department of Surgery  
University of Adelaide  
The Queen Elizabeth Hospital  
Woodville, SA  
Australia



Gail Gillespie  
Royal Perth Hospital  
Perth, WA  
Australia

Jonathan Golledge  
Vascular Biology Unit  
School of Medicine & Dentistry  
James Cook University  
Townsville, QLD  
Australia

George Hamilton  
University Department of Vascular Surgery  
Royal Free Hospital  
University College  
London  
UK

Mark Hamilton  
Department of Surgery  
University of Adelaide  
The Queen Elizabeth Hospital  
Woodville, SA  
Australia

Robert J Hinchliffe  
St George's Vascular Institute  
St George's Hospital  
London  
UK

Richard D Kenagy  
Department of Surgery  
University of Washington  
Seattle, WA  
USA

Paul Kerr  
Department of Pharmacology  
University of Alberta  
Alberta  
Canada

Michael MD Lawrence-Brown  
Curtin Health Innovation Research  
Institute  
Curtin University  
Perth, WA  
Australia

Brian Lepow  
The University of Arizona  
Department of Surgery  
Southern Arizona Limb Salvage Alliance  
Tucson, AZ  
USA

Kurt Liffman  
CSIRO Material Science & Engineering  
and School of Mathematical Sciences  
Monash University  
Melbourne, Vic  
Australia

Ian Loftus  
Department of Vascular Surgery  
St George's Hospital  
London  
UK

Mark J McCarthy  
Department of Surgery and Cardiovascular  
Sciences  
University of Leicester  
Leicester  
UK

Greg S McMahon  
Department of Surgery and Cardiovascular  
Sciences  
University of Leicester  
Leicester  
UK

Simon McRae  
Adult Haemophilia Treatment Centre  
SA Pathology  
Adelaide, SA  
Australia

Joseph L Mills  
The University of Arizona  
Southern Arizona Limb Salvage Alliance  
Tucson, AZ  
USA

Lyle Moldawer  
Department of Surgery  
University of Florida  
Gainesville, FL  
USA

John L Moran  
Faculty of Health Sciences  
University of Adelaide  
The Queen Elizabeth Hospital  
Woodville, SA  
Australia

Stephen Nicholls  
The Heart and Vascular Institute  
Cleveland Clinic  
Cleveland, OH  
USA

Ian M Nordon  
St George's Vascular Institute  
St George's Hospital  
London  
UK

Paul E Norman  
School of Surgery  
University of WA  
Fremantle, WA  
Australia

Karlheinz Peter  
Baker IDI Heart & Diabetes Institute  
Melbourne, Vic  
Australia

Frances Plane  
Department of Pharmacology  
University of Alberta  
Alberta  
Canada

Janet T Powell  
Imperial College  
London  
UK

Sandeep Prabhu  
Baker IDI Heart & Diabetes Institute  
Alfred Hospital  
Melbourne, Vic  
Australia

Rishi Puri  
The Heart and Vascular Institute  
Cleveland Clinic  
Cleveland, OH  
USA

Stephan A Schug  
Royal Perth Hospital  
Perth, WA  
Australia

Gregory S Schultz  
Department of Obstetrics and Gynaecology  
University of Florida  
Gainesville, FL  
USA

Rahul Sharma  
Baker IDI Heart & Diabetes Institute  
Alfred Hospital  
Melbourne, Vic  
Australia

Guo-Ping Shi  
Department of Cardiovascular Medicine  
Brigham & Women's Hospital  
Harvard Medical School  
Boston, MA  
USA

Michael Stacey  
University Department of Surgery  
Fremantle Hospital  
Fremantle, WA  
Australia

Ilija D Sutalo  
CSIRO Material Science & Engineering  
and Curtin Health Innovation  
Research Institute  
Curtin University  
Highett, Vic

Raymond Tam  
Department of Pharmacology  
University of Alberta  
Alberta  
Canada

Matthew Thompson  
St Georges Hospital Medical School  
London  
UK

Martin Veller  
Department of Surgery  
University of Witwatersrand  
Johannesburg  
South Africa

Mauro Vicaretti  
Department of Vascular Surgery  
Westmead Hospital  
Westmead, NSW  
Australia

Matt Waltham  
Academic Department of Surgery  
St Thomas' Hospital  
London  
UK

Matthew L White  
Vascular and Endovascular Surgery  
University of Arizona  
Tucson, AZ  
USA

David P Wilson  
School of Medical Sciences  
Discipline of Physiology  
University of Adelaide  
Adelaide SA  
Australia

Qingbo Xu  
Department of Cardiology  
Kings College  
University of London  
UK

# Detailed Contents

## CHAPTER 1 – ENDOTHELIUM

*Paul Kerr, Raymond Tam, Frances Plane*

- Introduction 1
- Endothelium-dependent regulation of vascular tone 2
- Angiogenesis 7
- Haemostasis 8
- Inflammation 9
- Conclusions 10
- References

## CHAPTER 2 – VASCULAR SMOOTH MUSCLE STRUCTURE AND FUNCTION

*David Wilson*

- Introduction 13
- Smooth muscle (vascular) structure
- Cytoskeleton 14
- Contractile myofilament
- Functional regulation of vascular smooth muscle: Neuronal, hormonal, receptor mediated 15
- Smooth muscle function 17
- Myofilament basis of smooth muscle contraction and relaxation
- Smooth muscle contraction and relaxation 18
- Ion channels important in the regulation of smooth muscle function
- Regulation of cellular  $\text{Ca}^{2+}$
- Sources of cytosolic  $\text{Ca}^{2+}$  entry 19
- Potassium channels
- Endothelial regulation of smooth muscle vasodilatation 20

## Smooth muscle proliferation and vascular remodeling 20

Summary 22

References

## CHAPTER 3 – ATHEROSCLEROSIS

*Gillian Cockerill, Qingbo Xu*

Introduction 25

Atherosclerotic lesions 26

Fatty streaks

Plaque or atheroma

Hypercholesterolemia and oxidised-LDL 27

High-density lipoproteins role in atheroprotection 28

Hypertension and biomechanical stress 29

Biomechanical stress-induced cell death 30

Biomechanical stress and inflammation 31

Biomechanical stress-induced smooth muscle cell proliferation 32

Infections and heat shock proteins

Infections

Heat shock proteins 33

Infections and HSP expression

Infections, sHSP and innate immunity 34

Immune responses 36

MHC class II antigens and T cells

Oxidised LDL as a candidate antigen

HSP60 as a candidate antigen 37

B2-glycoprotein Ib as a candidate antigen

Inflammation

C-reactive protein	38
CD40/CD40L	
<b>Summary and perspectives</b>	<b>39</b>
<b>References</b>	

## CHAPTER 4 – MECHANISMS OF PLAQUE RUPTURE

*Ian Loftus*

<b>Introduction</b>	<b>43</b>
<b>Evidence for the ‘plaque rupture theory’</b>	<b>44</b>
Coronary circulation	
Cerebral circulation	
<b>The role of individual components of the arterial wall</b>	
The endothelium	45
The lipid core	47
The cap of the plaque	49
Smooth muscle cells and collagen production	50
Macrophages and collagen degradation	51
The vessel lumen	56
<b>The role of angiogenesis in plaque rupture</b>	
<b>The role of infectious agents in plaque rupture</b>	<b>57</b>
<b>Risk prediction of plaque instability</b>	<b>58</b>
Imaging	
Blood markers	59
<b>Therapy aimed at plaque stabilisation</b>	
HMG Co-A reductase inhibitors	60
MMP inhibition	
Tissue inhibitors of metalloproteinases (TIMPs)	61
Synthetic MMP inhibitors	
Doxycycline	
ACE inhibitors	
<b>Summary</b>	<b>62</b>
<b>References</b>	<b>63</b>

## CHAPTER 5 – CURRENT AND EMERGING THERAPIES IN ATHEROPROTECTION

*Stephen Nicholls, Rishi Puri*

<b>Background</b>	<b>79</b>
<b>Pathology</b>	
<b>Risk factor modification</b>	<b>80</b>
Statins, LDL lowering and C-reactive protein	
The complexity of HDL	84
The controversy of triglycerides	87
Hypertension	
<b>Risk factor modification in the diabetic patient</b>	<b>89</b>
Glycaemic control	
Global risk factor reduction in diabetics	91
The metabolic syndrome	92
<b>Future targets</b>	<b>93</b>
<b>Conclusion</b>	
<b>References</b>	<b>94</b>

## CHAPTER 6 – MOLECULAR APPROACHES TO REVASCULARISATION IN PERIPHERAL VASCULAR DISEASE

*Greg S McMahon, Mark J McCarthy*

<b>Introduction</b>	<b>103</b>
<b>Mechanisms of vascular growth</b>	
Vasculogenesis	
Angiogenesis	104
Neovessel maturation	105
Microvascular network maturation	106
Arteriogenesis	
<b>Therapeutic induction of vascular growth</b>	<b>107</b>
Delivery of molecular activators of vascular growth	
Angiogenic activators	108
Arteriogenic activators	109
Clinical trials for angiogenic therapy of peripheral vascular disease	
<b>Conclusions</b>	<b>110</b>
<b>References</b>	

## CHAPTER 7 – BIOLOGY OF RESTENOSIS AND TARGETS FOR INTERVENTION

*Richard Kenagy*

**Introduction** 115

**Mechanisms of restenosis**

Thrombosis 116

Remodelling

Intimal hyperplasia 123

Sequence of events after injury

Origin of intimal cells 125

Inflammation 126

Role of ECM production 127

**The contribution of specific factors to restenosis**

Growth factors/cytokines

Inhibitors 128

Coagulation and fibrinolytic factors 129

Matrix metalloproteinases

Extracellular matrix/receptors

**Targets for intervention** 130

Intracellular signalling molecules

mTOR and microtubules

Transcription factors

miRNA 131

Inflammation targets

Brachytherapy

Extracellular targets and cell-based therapies

Angiotensin pathway

Cell-based therapies 132

Differential effects on endothelium and SMCs

Delivery devices

Prevention versus reversal of restenosis

**Conclusions** 133

**References** 134

## CHAPTER 8 – VASCULAR ARTERIAL HAEMODYNAMICS

*Michael Lawrence Brown, Kurt Liffman, James Semmens, Ilija Sutalo*

**Introduction** 153

Laplace's law of wall of tension 154

Newtonian fluid 155

Non-Newtonian fluid

Poiseuille flow 158

Bernoulli's equation

Young's modulus and pulsatile flow 159

Mass conversion 161

Reynold's number

Arterial dissection, collateral circulation and competing flows 163

Shear stress and pressure 164

Forces on graft systems 165

Case 1 – The cylindrical graft 168

Case 2 – The windsock graft

Case 3 – The curved graft 169

Case 4 – The symmetric bifurcated graft

**Computational modelling** 170

**Recent development and future directions** 171

**Conclusions** 172

**References** 173

## CHAPTER 9 – PHYSIOLOGICAL HAEMOSTASIS

*Simon McRae*

**Introduction** 177

**Primary haemostasis**

Platelets

Platelet adhesion

Platelet activation and shape change 179

Platelet aggregation 180

**Interactions between primary and secondary haemostasis** 181

**Secondary haemostasis**

**The coagulation cascade** 182

Initiation 183

Amplification

Propagation 184

Normal inhibitors of coagulation

Fibrinolysis 185

**Conclusions** 186

**References**

## CHAPTER 10 – HYPERCOAGULABLE STATES

*Simon McRae*

### **Introduction** 189

### **Classification of thrombophilia**

Inherited thrombophilia 190

Type 1 conditions

Antithrombin deficiency

Protein C and Protein S deficiency

Type 2 conditions 191

Factor V Leiden

The prothrombin (G20210A) gene mutation

FVL/PGM compound heterozygotes

Other inherited conditions

Acquired thrombophilia 192

Antiphospholipid antibodies

Heparin induced thrombocytopenia

Myeloproliferative disorders 193

Potential reasons for performing thrombophilia testing

Patients with venous thrombosis and their relatives

Providing an understanding of the aetiology of a thrombotic event

Determining risk of recurrence and therefore optimal duration of anticoagulation 194

Determining the need for primary prophylaxis in asymptomatic family members 195

Making decisions regarding the use of the oral contraceptive pill 196

Determining the need for thromboprophylaxis during pregnancy

Patients with arterial thrombosis

**Potential detrimental effects of thrombophilia testing** 197

**Conclusion**

**References**

## CHAPTER 11 – PLATELETS IN THE PATHOGENESIS OF

## VASCULAR DISEASE AND THEIR ROLE AS A THERAPEUTIC TARGET

*Sandeep Prabhu, Rahul Sharma,  
Karlheinz Peter*

### **Introduction** 201

### **Platelet function – Adhesion and activation**

Platelet adhesion 202

Platelet activation 203

Mediators of platelet activation and ‘outside in’ signalling

Thrombin and collagen 204

Adenosine diphosphate (ADP)

Thromboxane A2 (TXA2)

Adrenaline 206

Second messenger systems 207

Physiological consequences of platelet activation

The GP IIb/IIIa receptor and ‘inside-out’ signalling

Granule exocytosis 208

Activation-induced conformational change of platelets

### **Platelets and atherosclerosis** 209

Role of platelets in the initiation of the atherosclerosis

Role of the platelets in the progression of the atherosclerosis

Role of platelets in vulnerable plaques and plaque rupture

### **Current and future anti-platelet agents** 210

Aspirin (salicylic acid)

Thienopyridines 211

Clopidogrel

Prasugrel 213

Ticlopidine

Ticagrelor

GPIIb/IIIa Antagonists

Other anti-platelet agents and promising new developments 214

### **Platelet function testing** 215

Light-transmission aggregometry

Whole blood aggregometry 217  
 VerifyNow® Assay  
 Flow cytometry 218

## References

## CHAPTER 12 – PATHOGENESIS OF AORTIC ANEURYSMS

*Jonathan Golledge, Guo-Ping Shi,  
 Paul E Norman*

**Introduction** 227

**Differences between thoracic and abdominal aortic aneurysms** 228

**Summary of current theories and stages of AAA evolution**

**Atherosclerosis and AAA**

**Immune mechanisms in AAA** 229

**Extracellular matrix dysfunction** 232

**Infection** 233

**Biomechanical forces**

**Angiogenesis**

**Intra-luminal thrombus**

**Extracellular matrix proteolysis** 234

**Genetics** 236

**AAA rupture** 237

Biomechanical factors in aneurysms rupture

The role of enzymes in AAA rupture

Role of intraluminal thrombus in aneurysm rupture 238

**Future research**

**References**

## CHAPTER 13 – PHARMACOLOGICAL TREATMENT OF ANEURYSMS

*Matthew Thompson, Janet T Powell*

**Background** 247

**Screening programmes**

**Pathophysiology** 248

**Therapeutic strategies**

Beta blockade

Modification of the inflammatory

response 249

Non-steroidal anti-inflammatories

Matrix metalloproteinase (MMP)

inhibition

Anti-chlamydial therapy 250

**Drugs acting on the renin/angiotensin axis**

**HMG Co-A reductase inhibitors** 251

**The future – Data from recent**

**experimental studies**

**References**

## CHAPTER 14 – PATHOPHYSIOLOGY OF AORTIC DISSECTION AND CONNECTIVE TISSUE DISORDERS

*Mark Hamilton*

**Introduction** 255

Embryology of thoracic aorta and arch vessels

Haemodynamics of thoracic compared to abdominal aorta 257

Sizes of normal aorta

**Classification of aortic syndromes**

Acute/Chronic

DeBakey classification of class 1 dissection – Type 1, 2, and 3

Stanford classification 258

European task force

**Pathogenesis of thoracic aortic dissection**

Classical thoracic aortic dissection (class 1 dissection) 260

Intramural haematoma (class 2 aortic dissection) 261

Penetrating aortic ulcer (class 4 aortic dissection) 262

**Complications of acute aortic syndromes** 263

Visceral ischaemia /malperfusion syndromes

Fate of the false lumen

Aneurysmal degeneration and rupture 264

**Connective tissue disorders and acute aortic syndromes**



Marfan syndrome	
Fibrillin and Marfan syndrome	265
The role of transforming growth factor beta in development of the vascular system in health and disease	266
Ehlers-Danlos syndrome	267
Diagnosis of Ehlers-Danlos syndrome	268
Loeys-Deitz syndrome	270
Familial thoracic aortic aneurysm disease	271
Bicuspid aortic valve	273
Turners Syndrome	
<b>Summary</b>	<b>274</b>
<b>Reference list</b>	

## CHAPTER 15 – BIOMARKERS IN VASCULAR DISEASE

*Ian M Nordon, Robert J Hinchliffe*

<b>Introduction</b>	<b>277</b>
<b>What is a biomarker?</b>	
<b>Types of biomarkers</b>	
A classical clinical example	278
<b>Potential value of biomarkers in vascular disease</b>	<b>279</b>
<b>Biomarker discovery steps</b>	<b>280</b>
<b>AAA biomarkers</b>	
Circulating extracellular matrix markers	281
Matrix-degrading enzymes	283
Proteins associated with thrombosis	
Markers of inflammation	284
<b>Biomarkers of AAA rupture</b>	<b>285</b>
<b>Biomarkers following endovascular repair</b>	
Inflammation	287
Lipid accumulation	
Apoptosis	
Thrombosis	
Proteolysis	288
<b>Challenges in biomarkers discovery</b>	
<b>Future work</b>	
<b>Conclusion</b>	<b>289</b>
<b>References</b>	

## CHAPTER 16 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VASCULITIS AND RAYNAUD'S PHENOMENON

*Martin Veller*

<b>Vasculitides</b>	<b>295</b>
<b>Introduction</b>	
<b>Classification of vasculitides</b>	<b>296</b>
<b>Clinical presentation of vasculitides</b>	
<b>Investigations of vasculitides</b>	
<b>Principles of treatment of vasculitides</b>	<b>297</b>
<b>The vasculitides of specific interest to vascular surgeons</b>	<b>298</b>
Giant cell arteritis	
Takayasu's arteritis	299
Thromboangitis obliterans (Buerger's disease)	300
Behcet's disease	301
Polyarteritis nodosa	302
Vasculitides secondary to connective tissue diseases	303
Systemic lupus erythematosus (SLE)	
Antiphospholipid antibody syndrome (APS)	304
Rheumatoid arthritis	305
Scleroderma	
Infective vasculitides	306
Human immunodeficiency virus (HIV)	
<b>Pathophysiology and principles of Raynaud's phenomenon</b>	<b>307</b>
Prevalence of Raynaud's phenomenon	308
Clinical findings in Raynaud's phenomenon	309
Diagnosis of Raynaud's phenomenon	
<b>Prognosis</b>	<b>310</b>
<b>Treatment</b>	
<b>Recommendations</b>	<b>311</b>
<b>References</b>	<b>312</b>

## CHAPTER 17 – SIRS, SEPSIS AND

**MULTIORGAN FAILURE***Vishwanath Biradar, John Moran***Epidemiology 315****Historical perspectives and definition 316****Risk factors for sepsis 317**

Causative agents

**Pathophysiology of sepsis**

innate immunity and toll-like receptors (TLRs) 319

Proinflammatory response

Coagulation cascade

**Multorgan dysfunction syndrome (MODS) 320**

Epithelial and endothelial dysfunction

Immune suppression and apoptosis

Sepsis, circulatory failure and organ dysfunction

**Management 322**

Steroids 323

Recombinant human activated protein C (rhAPC) 324

Glucose control 325

Renal replacement therapy

3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors (HMG-CoA) 326

Other adjuvant therapies in sepsis

Cytokines and anticytokine therapies

Pooled immunoglobulin (IVIG)

Acute respiratory distress syndrome (ARDS) 327

**References****CHAPTER 18 –  
PATHOPHYSIOLOGY OF  
REPERFUSION INJURY***Prue Cowled, Rob Fitridge***Introduction 331****Ischaemia**

ATP and mitochondrial function

Gene expression during ischaemia 332

**Reperfusion 333**

Reactive oxygen species

Eicosanoids 334

Nitric Oxide 335

Endothelin 336

Cytokines

Neutrophil and endothelial interactions 338

Complement activation 340

**Tissue destruction 341**

Proteases and metalloproteinases

Apoptotic cell death during ischaemia-reperfusion injury

No-reflow phenomenon 342

**Therapeutic approaches to IRI**

Ischaemic preconditioning

Ischaemic post-conditioning 343

Conditioning effects of volatile anaesthetics

Pharmacological treatments 344

**Summary 345****References****CHAPTER 19 – COMPARTMENT  
SYNDROME***Edward Choke, Robert Sayers, Matthew Bown***Definition 351****Acute limb compartment syndrome**

Incidence

Anatomy/physiology 352

Aetiology/pathophysiology

Clinical presentation 354

Investigation 355

Treatment 357

Complication of LCS 359

Outcome 360

**Acute abdominal compartment syndrome**

Incidence 361

Aetiology

Pathological effects of raised intra-abdominal pressure 362

Clinical presentation 363

Investigation

Treatment 364

Complications of surgical decompression

Outcome 367

References 368

## CHAPTER 20 – PATHOPHYSIOLOGY OF PAIN

*Stephan Schug, Helen Daly, Kathryn Stannard*

**Introduction** 375

**Peripheral mechanisms**

Nociception/transduction

Conduction 376

**Spinal cord mechanisms**

Ascending systems 377

Descending control

**Pain modulation** 378

Peripheral sensation

Central sensitisation in the dorsal horn

**Neuropathic pain** 379

Mechanisms of neuropathic pain

Peripheral mechanisms

Spontaneous ectopic discharge

Altered gene expression

Spared sensory neurons

Involvement of the sympathetic nervous system 380

Collateral sprouting

Effects of bradykinin

Central mechanisms

Wind up

Central sensitization 381

Central disinhibition

Expansion in receptive field size (recruitment)

Immediate early gene expression

Anatomical re-organisation of the spinal cord

Contribution of glial cells to pain conditions 382

**Symptoms of neuropathic pain**

Stimulus-dependent pain

Stimulus-independent pain 383

Sympathetically maintained pain (SMP)

**Neuropathic pain syndromes**

Peripheral neuropathies

Central neuropathies 385

**References**

## CHAPTER 21 – POST-AMPUTATION PAIN

*Stephan Schug, Gail Gillespie*

**Introduction** 389

**Classification and incidence of post-amputation pain syndromes**

Stump pain

Phantom sensation 390

Phantom limb pain

**Pathophysiology of post-amputation pain syndromes**

Peripheral factors

Spinal factors 391

Supraspinal factors

**Current pathophysiological model of post-amputation pain syndromes** 392

**Prevention of post-amputation pain**

Perioperative lumbar epidural blockade

Peripheral nerve blockade 393

NMDA antagonists

**Evaluation of the patient with post-amputation pain syndromes**

Examination

**Therapy of post-amputation pain syndromes** 394

Calcitonin

Ketamine

Analgesic and Co-analgesic compounds

Opioids 395

Gabapentin

Clonazepam

Lidocaine

Carbamazepine

Tricyclic antidepressants (TCA)

Selective serotonin reuptake inhibitors

Baclofen

Capsaicin

**Symptomatic treatment of pain components** 396

**Neuropharmacological therapies**

Invasive therapies  
 Electroconvulsive therapy (ECT)  
 Nerve blockade  
 Spinal cord stimulation  
 Implantable intrathecal delivery systems  
 Dorsal root entry zone (DREZ) lesions  
 Psychological therapy 397

**Future aims**

**References**

**CHAPTER 22 – TREATMENT OF NEUROPATHIC PAIN**

*Stephan Schug, Kathryn Stannard*

**Introduction 401**

**Principles of treatment**

**Pharmacological treatment 402**

Opioids

Recommendations for clinical use of opioids

Tramadol

Mechanism of action

Efficacy 403

Adverse effects

Recommendations for clinical use of tramadol in neuropathic pain

Antidepressants

Tricyclic antidepressants (TCAs)

Mechanism of action 404

Adverse effects

Selective serotonin re-uptake inhibitors (SSRIs)

Serotonin/Noradrenaline reuptake inhibitors (SNRIs) 405

Recommendations for clinical use of antidepressants as analgesics

Anticonvulsants

Mechanism of action 406

Individual medications

Clonazepam

Gabapentin

Pregabalin 407

Carbamazepine

Sodium valproate 408

Phenytoin

Lamotrigene

Recommendations for clinical use of anticonvulsants as analgesics

Local anaesthetics and antiarrhythmics 409

Mechanism of action

Lignocaine

Mexiletine

Recommendations for clinical use of lignocaine and mexiletine in neuropathic pain

N-methyl-D-aspartate-receptor antagonists (NMDA)

Ketamine 410

Other NMDA antagonists

Miscellaneous compounds for systemic use

Clonidine

Efficacy

Baclofen

Levodopa 411

Cannabinoids

Topical treatments

Lignocaine 5% medicated plaster

Capsaicin 412

Mechanism of action

Efficacy

**Non-pharmacological therapy**

Transcutaneous electrical nerve stimulation (TENS)

Spinal cord stimulation (SCS) 413

Sympathetic nerve blocks

Neurosurgical destructive techniques

Cognitive behaviour therapy

**References 414**

**CHAPTER 23 – PRINCIPLES OF WOUND HEALING**

*Gregory Schultz, Gloria Chin, Lyle Moldawer, Robert Diegelmann*

**Introduction 423**

**Phases of acute wound healing**

Haemostasis

- Inflammation 426
  - Neutrophils 427
  - Macrophages 428
- Proliferative phase 429
  - Fibroblast migration 430
  - Collagen and extracellular matrix production
    - Angiogenesis 431
  - Granulation 432
  - Epithelialization
  - Remodelling 433
- Summary of acute wound healing 435
- Comparison of acute and chronic wounds**
  - Normal and pathological responses to injury
  - Biochemical differences in the molecular environments of healing and chronic wounds 436
  - Biological differences in the response of chronic wound cells to growth factors 439
- From bench to bedside**
  - Role of endocrine hormones in the regulation of wound healing
  - Molecular basis of chronic non-healing wounds
  - Chronic venous stasis ulcers 441
  - Pressure ulcers
- Future concepts for the treatment of chronic wounds 442**
  - Bacterial biofilms in chronic wounds 443
- Conclusion 445**
- References**

## CHAPTER 24 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VARICOSE VEINS

*Andrew Bradbury*

- Introduction 451**
- Anatomy**
- Histology 452**
- Physiology**

- Varicose veins 453**
- Valvular abnormalities**
- Muscle pump failure 455**
- Venous recirculation**
- Recurrent varicose veins**
  - New varicose veins
  - Persistent varicose veins
  - True recurrent varicose veins 456
- Cellular and molecular biology of varicose veins**
- Conclusion 457**
- References**

## CHAPTER 25 – CHRONIC VENOUS INSUFFICIENCY AND LEG ULCERATION: PRINCIPLES AND VASCULAR BIOLOGY

*Michael Stacey*

- Definitions 459**
  - Chronic venous insufficiency
  - Leg ulceration
    - Assessment of cause of leg ulceration 460
- Epidemiology 461
- Pathophysiology
  - Venous abnormality
  - Effect of ambulatory venous hypertension on the tissues in the leg 463
  - Influence of venous disease on the wound healing process 465
    - Genetic associations with venous ulceration 466
- Assessment of venous function 467**
- Treatment of venous ulceration**
  - Compression therapy
  - Dressings 468
  - Surgery
    - Prevention of venous ulcer recurrence 470
    - Sclerotherapy and other techniques to obliterate surface and perforating veins
    - Other therapies 471
- References**

CHAPTER 26 –  
PATHOPHYSIOLOGY AND  
PRINCIPLES OF MANAGEMENT  
OF THE DIABETIC FOOT

*David Armstrong, Timothy Fisher, Brian  
Lepow, Matthew White, Joseph Mills*

- Introduction** 475
- Pathophysiology of the diabetic foot** 476
- Neuropathy
  - Structural abnormalities/gait abnormalities
  - Angiopathy 478
- Diagnosis**
- History and rapid visual screening
  - Neurological examination 479
    - Monofilament testing
    - Vibration testing
  - Dermatologic examination 480
  - Anatomy of occlusive disease – vascular examination
  - Prediction of wound healing: assessment of perfusion 481
  - Arterial imaging
  - Soft tissue imaging 482
- Classification systems** 483
- Diabetes mellitus foot risk classification
  - University of Texas wound classification system
- Clinical problems and principles of management** 484
- Ulceration
    - Epidemiology and risk factors
    - Offloading
  - Non-vascular surgical treatment 485
    - Class I – Elective 486
    - Class II – Prophylactic
    - Class III – Curative
    - Class IV – Emergency (urgent)
  - Post-operative management
  - Infections 487
  - Charcot arthropathy
- Prevention** 490
- Conclusion** 492
- References**

CHAPTER 27 – LYMPHOEDEMA  
– PRINCIPLES, GENETICS AND  
PATHOPHYSIOLOGY

*Matt Waltham*

- Introduction** 497
- Classification of lymphoedema**
- Classification of primary lymphoedema 498
- The genetics of lymphangiogenesis in primary lymphoedema** 500
- Milroy's disease
  - Lymphoedema – distichiasis syndrome 501
  - Hypotrichosis – lymphoedema – telangiectasia syndrome 502
  - Meige disease (primary non-syndromic lymphoedema)
  - Other primary lymphoedema disorders 503
- Structure and development of the lymphatic circulation**
- Clinical aspects of lymphoedema** 505
- Summary**
- References**

CHAPTER 28 – GRAFT  
MATERIALS PAST AND FUTURE

*Mital Desai, George Hamilton*

- The pathophysiology of graft healing** 511
- The peri-anastomotic area
  - Healing of prosthetic grafts 512
    - The healing process of the anastomosis
    - Graft porosity and permeability
- Physical properties of prosthetic materials** 514
- Tubular compliance
  - Anastomotic compliance mismatch
  - The compliance hypothesis of graft failure
- Synthetic grafts** 515
- Newer developments of Dacron grafts
  - Modifications and newer developments of PTFE grafts 517
  - Polyurethane grafts

Newer developments of polyurethane vascular grafts	518
Biological vascular grafts	519
Newer developments of biological vascular grafts	520
<b>Prosthetic graft modifications</b>	
Modifications to reduce graft infection	
Modifications to improve patency	521
Nanocomposite grafts	
<b>Endothelial cell seeding</b>	522
Single stage seeding	
Two stage seeding	
<b>Vascular tissue engineering</b>	
Non-degradable polymer and cell seeding	523
Bioresorbable and biodegradable polymers	
Combined bioresorbable and tissue engineered grafts	524
Mechanical conditioning of seeded vascular cells	
Alternative scaffolds	
Tissue-engineered grafts	525
<b>Graft materials for aortic endografts</b>	526
<b>The future</b>	
<b>References</b>	527

## CHAPTER 29 – PATHOPHYSIOLOGY OF VASCULAR GRAFT INFECTIONS

*Mauro Vicaretti*

<b>Introduction</b>	537
<b>Natural history of prosthetic vascular graft infections</b>	
<b>Mechanism of graft contamination at operation</b>	538
<b>Pathogenesis of graft infections</b>	
<b>Bacteriology of vascular graft infections</b>	
<b>Investigations for detection of prosthetic graft infections</b>	539
History and physical examination	
Laboratory investigations	
Diagnostic imaging	540
<b>Management of prosthetic graft infections</b>	
Prevention	
Reduction of prosthetic vascular graft infection with rifampicin bonded gelatin sealed Dacron	541
<b>Established infection</b>	
Antibiotic therapy	
Operative management	
<b>Conclusion</b>	542
<b>References</b>	

## **Acknowledgements**

The Editors gratefully acknowledge the outstanding contributions of each Author involved in this reference book. We would also like to acknowledge the invaluable efforts of Ms Sheona Page who has worked tirelessly on this project. We would also like to thank Prue Cowled PhD and Ms Cayley Wright for their assistance.



# Abbreviation List

a1-PI	a1-protease inhibitor
5-HT	5-Hydroxytryptamine/Serotonin
AAA	Abdominal aortic aneurysm
AAS	Acute aortic syndrome
AAV	Adeno-associated viruses
ACE	Angiotensin converting enzyme
ACS	Acute coronary syndrome
ACS	Abdominal compartment syndrome
ACTH	Adrenocorticotrophic hormone
ADAMTS	A disintegrin and metalloproteinase with thrombospondin motifs
ADP	Adenosine diphosphate
AIDS	Acquired immune deficiency syndrome
ALI	Acute lung injury
AMP	Adenosine monophosphate
AMPA	$\alpha$ -amino-3 hydroxy-5-methylisoxazole
ANA	Anti-nuclear antibody
ANCA	Anti-neutrophil cytoplasmic antibody
AOD	Aortic occlusive disease
AP1	Activated protein 1
APC	Activated protein C
APC	Antigen presenting cell
APLAS	Antiphospholipid antibody syndrome
ApoA1	Apolipoprotein A1
ApoE	Apolipoprotein E
APS	Antiphospholipid antibody syndrome
APTT	Activated partial thromboplastin time

ARDS	Acute respiratory distress syndrome
AT	Antithrombin
ATP	Adenosine triphosphate
AVP	Ambulatory venous thrombosis
$\beta$ 2-GPI	$\beta$ 2-glycoprotein Ib
bFGF	Basic fibroblast growth factor
BKCa	Large conductance calcium activated potassium channel
BMPs	Bone morphogenetic proteins
BMS	Bare metal stent
CAD	Coronary artery disease
CaM	Calmodulin
CAM	Cell adhesion molecule
cAMP	Cyclic adenosine monophosphate
CCK	Cholecystokinin
cGMP	Cyclic guanine monophosphate
CD	Cluster of differentiation
CD40L	Cluster of differentiation 40 ligand
CEA	Carotid endarterectomy
CETP	Cholesteryl ester transfer protein
CFD	Computational fluid dynamics
CG	Cationized gelatin
CGRP	Calcitonin gene regulated peptide
CHD	Coronary heart disease
CI	Confidence interval
CIMT	Carotid intimal-media thickness
c-JNK	c-Jun N-terminal kinase
CK-MB	Creatinine kinase (Myocardial specific)
CNCP	Chronic noncancer pain
cNOS	Constitutive nitric oxygen synthase enzyme
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
CROW	Charcot restraint orthotic walker
CRRT	Continuous renal replacement therapy

CRP	C-reactive protein
CRPS	Complex regional pain syndromes
CT	Computational tomography
CTA	Computed tomographic angiography
CTD	Connective tissue disorders
CTGF	Connective tissue growth factor
CYP	Cytochrome P450
CVD	Cardiovascular disease
CVI	Chronic venous insufficiency
DAG	Diacylglycerol
DES	Drug-eluting stent
DRG	Dorsal root ganglion
DNA	Deoxyribonucleic acid
DSA	Digital subtraction arteriography
DTS	Dense tubular system
DVT	Deep vein thrombosis
EC	Endothelial cell
ECM	Extracellular matrix
EDCF	Endothelium-derived contracting factor
EDH	Endothelium-dependent hyperpolarisation
EDS	Ehlers-Danlos syndrome
EET	Epoxyeicosatrienoic acids
ELAM-1	Endothelial-leukocyte adhesion molecule-1
ELG	Endoluminal grafts
ELISA	Enzyme linked immunosorbent assay
$E_K$	Equilibrium potential
$E_M$	Membrane potential
eNOS	Endothelial nitric oxide synthase enzyme
EPC	Endothelial progenitor cells
EPCR	Endothelial protein C receptor
ePTFE	Expanded polytetrafluoroethylene
ERK	Extracellular signal-regulated kinase
ESR	Erythrocyte sedimentation rate

ET	Essential thrombocytosis
ET-1	Endothelin 1
EVAR	Endovascular aortic aneurysm repair
EVLA	Endovenous LASER ablation
FDA	Food and drug administration
FDPs	Fibrin degradation products (soluble)
FGF	Fibroblast growth factor
FGF-2	Fibroblast growth factor 2
FMN	Flavin mononucleotide
FVL	Factor V Leiden
GABA	Gamma-aminobutyric acid
GABA B	Gamma-aminobutyric acid subtype B
G-CSF	Granulocyte colony stimulating factor
GMCSF	Granulocyte-macrophage colony stimulating factor
GP	Glycoprotein
GPCR	G-protein coupled receptor
GSV	Great saphenous vein
HDL	High density lipoprotein
HDL-C	High density lipoprotein cholesterol
HIF	Hypoxia inducible factor
HIT	Heparin induced thrombocytopenia
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HMG Co-A	Hydroxymethylglutaryl coenzyme-A
HMW	High molecular weight
HPETE	Hydroperoxyeicosatetraenoic acid
HETE	Hydroxyeicosatetraenoic acids
HR	Hazard ratio
hsCRP	High-sensitive C-reactive protein
HSP	Heat shock protein
HUV	Human umbilical vein
IAH	Intra-abdominal hypertension

IAP	Intra-abdominal pressure
IAPP	Intra-abdominal perfusion pressure
ICAM-1	Inter-cellular adhesion molecule-1
ICAM-2	Inter-cellular adhesion molecule-2
ICP	Intra-compartmental pressure
ICU	Intensive care unit
IFN	Interferon
IGF-1	Insulin-like growth factor-1
IHD	Ischemic heart disease
IL	Interleukin
IL-1	Interleukin-1
IL-1 $\alpha$	Interleukin-1 alpha
IL-1 $\beta$	Interleukin-1 beta
IL-6	Interleukin-6
IL-8	Interleukin-8
ILT	Intraluminal thrombus
IKCa	Intermediate conductance calcium-activated potassium channels
IMH	Intramural haematoma
IMP	Inosine monophosphate
iNOS	Inducible nitric oxide synthase enzyme
IP(3)	1,4,5-inositol triphosphate
IRI	Ischemia reperfusion injury
IVIG	Intravenous pooled immunoglobulin
IVUS	Intravascular ultrasound
KGF	Keratinocyte growth factor
KGF-2	Keratinocyte growth factor-2
LAP	Latency associated peptide
LCS	Limb compartment syndrome
LDL	Low density lipoprotein
LDS	Loeys-Dietz syndrome
LLC	Large latent complex
LEC	Lymphatic endothelial cells

LFA-1	Lymphocyte function-associated antigen-1
LO	Lipoxygenase
LOX	Lysyl oxidase
LOPS	Loss of protective sensation
LPA	Lysophosphatidic acid
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
LTGFBP	Latent TGF binding protein
MAC-1	Macrophage-1 antigen
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
M-CSF	Macrophage-colony stimulating factor
MFS	Marfan syndrome
MHC	Major histocompatibility
MI	Myocardial infarction
MIP-1	Macrophage inflammatory protein-1
MLC <sub>20</sub>	Myosin light chain <sub>20</sub>
MLCK	Myosin light chain kinase
MLCP	Myosin light chain phosphatase
MMP	Matrix metalloproteinase
MODS	Multiple organ dysfunction syndrome
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MRSE	Methicillin resistant <i>Staphylococcus epidermidis</i>
MRTA	Magnetic resonance tomographic angiography
MTHFR	Methylenetetrahydrofolate reductase
MT-MMP	Membrane-type MMP
MVPS	Mitral valve prolapse syndrome
NADPH	Nicotinamide adenine dinucleotide phosphate
NGF	Nerve growth factor

NFκB	Nuclear factor kappa B
NiTi	Nitinol
NJP	Non-junctional perforators
NMDA	N-methyl-D-aspartate
NNH	Number needed to harm
NNT	Number needed to treat
NO	Nitric oxide
NOS	Nitric oxide synthase enzyme
NSAID	Non-steroidal anti-inflammatory drug
NV	Neovascularisation
OCP	Oestrogen/progesterone contraceptive pill
OPN	Osteopontin
OPG	Osteoprotegerin
OR	Odds ratio
OxLDL	Oxidised low density lipoprotein
PAD	Peripheral arterial disease
PAF	Platelet activating factor
PAI	Plasminogen activator inhibitor
PAI-1	Plasminogen activator inhibitor-1
PAR	Protease activated receptor
PAR-1	Protease activated receptor-1
PAR-4	Protease activated receptor-4
PAU	Penetrating aortic ulcer
PC	Protein C
PCA	Poly (carbonate-urea) urethane
PCI	Percutaneous coronary intervention (angioplasty)
PCWP	Pulmonary capillary wedge pressure
PDGF	Platelet-derived growth factor
PDGFβ	Platelet-derived growth factor-β
PDS	Polydioxanone
PECAM-1	Platelet-endothelial cell adhesion molecule-1
PEDF	Pigment epithelium-derived factor
PES	Paclitaxel-eluting stent

PET	Positron emission tomography
PF4	Platelet factor 4
PGI <sub>2</sub>	Prostacyclin
PGG <sub>2</sub>	Prostaglandin G <sub>2</sub>
PGH <sub>2</sub>	Prostaglandin H <sub>2</sub>
PGEI <sub>2</sub> /PGI <sub>2</sub>	Prostaglandin I <sub>2</sub>
PGN	Peptidoglycan
PHN	Postherpetic neuropathy
PHZ	Para-anastomotic hyper-compliant zone
PI3K	Phosphatidylinositol 3-kinase
PIP2	Phosphatidylinositol 4,5-bisphosphate
PLC	Phospholipase C
PLOD	Procollagen lysyl hydroxylase
PMCA	Plasma membrane Ca <sup>2+</sup> APTases
PMN	Polymorphonuclear leukocyte
POSS	Polyhedral oligomeric silsesquioxanes
PPAR	Peroxisomal proliferation activating receptor
PPI	Proton pump inhibitor
PRV	Polycythaemia rubra vera
PS	Protein S
PSGL-1	P-selectin glycoprotein ligand-1
PT	Prothombin time
PTCA	Percutaneous coronary angioplasty
PTFE	Polytetrafluoroethylene
PTS	Post-thrombotic syndrome
PUFA	Polyunsaturated fatty acid
PVI	Primary valvular incompetence
rAAA	Ruptured AAA
Rac	Ras activated cell adhesion molecule
RANTES	Regulated upon activation, normal T cell expressed and secreted
RAS	Renin angiotensin system
RCT	Randomised controlled trial



RF	Rheumatoid factor
RFA	Radiofrequency ablation
rhAPC	Recombinant human activated protein C
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RR	Relative risk
RSD	Reflex sympathetic dystrophy
S1P	Sphingosine-1-phosphate
SAPK	Stress-activated protein kinase
SCF	Stem cell factor
SCS	Spinal cord stimulation
ScvO2	Superior vena cava venous oxygen saturation
SDF-1	Stromal-cell-derived factor-1
SERCA	Sarco/endoplasmic reticulum CaATPases
SEP	Serum elastin peptides
SES	Sirolimus-eluting stent
SEPS	Subfascial endoscopic perforator surgery
SFA	Superficial femoral artery
SFJ	Sapheno-femoral junction
SIRS	Systemic inflammatory response syndrome
SKCa	Small conductance calcium-activated potassium channels
SLE	Systemic lupus erythematosus
SMA	Smooth muscle alpha actin
SMC	Smooth muscle cell
SMP	Sympathetically maintained pain
SNARE	Soluble N-ethylmaleimide-sensitive factor activating protein receptors
SNP	Single nucleotide polymorphisms
SNRI	Serotonin/Noradrenaline reuptake inhibitors
SPJ	Sapheno-popliteal junction
SPP	Skin perfusion pressure
SR	Sarcoplasmic reticulum
SSRIs	Selective serotonin re-uptake inhibitors
SSV	Small saphenous vein

SVT	Superficial thrombophlebitis
STIM1	Stromal interacting molecule 1
T $\alpha$ CE	TNF $\alpha$ converting enzyme
TAAD	Thoracic aortic aneurysm disease
TAD	Thoracic aortic dissection
TAFI	Thrombin-activatable fibrinolysis inhibitor
Tc-99 MDP	Technetium-99 methylene diphosphonate
TCA	Tricyclic antidepressant
TCC	Total contact cast
TCR	T-cell receptor
TENS	Transcutaneous electrical nerve stimulation
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
TGF	Transforming growth factor
TGF- $\alpha$	Transforming growth factor-alpha
TGF- $\beta$	Transforming growth factor-beta
TGL	Triglycerides
Th	T helper
TIA	Transient ischemic attack
TIMP	Tissue inhibitors of metalloproteinase
TLR	Toll-like receptors
TNF	Tumour necrosis factor
TNF- $\alpha$	Tumour necrosis factor-alpha
tPA	Tissue-type plasminogen activator
TRP	Transient receptor potential
TRPC	Transmembrane receptor potential canonical
TRPV1	Transmembrane receptor potential Vanilloid-type
TXA2	Thromboxane A2
uPA	Urokinase
UT	University of Texas
VCAM	Vascular cell adhesion molecule
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor

VEGF-R	Vascular endothelial growth factor receptor
VIP	Vasoactive intestinal peptide
VLA-1	Very late activating antigen-1
VOCC	Voltage operated calcium channels
VPT	Vibratory perception threshold
VSMC	Vascular smooth muscle cells
VTE	Venous thromboembolism
VV	Varicose veins
vWF	von Willebrand factor
XO	Xanthine oxidase

## 6 • Molecular Approaches to Revascularization in Peripheral Vascular Disease

GREG S. MCMAHON, MARK J. MCCARTHY

Department of Surgery and Cardiovascular Sciences, University of Leicester, Leicester, UK

### INTRODUCTION

Currently, treatment options for peripheral vascular disease include angioplasty and reconstructive surgery. An attractive, less invasive alternative could involve the revascularization of ischaemic tissue by the induction of vascular growth. It would be particularly welcome for patients in whom current approaches are difficult or prone to failure, including those with conditions that make surgical intervention unsafe, patients with diffuse occlusive disease and those in whom there is significant downstream microvascular disease. Recent years have witnessed major advances in the understanding of the molecular mechanisms underlying vascular formation and remodelling, as well as the identification of key molecules controlling these processes. Most research has focused on the induction of new vessel formation by stimulating angiogenesis and this has been the goal of the clinical trials directed at peripheral vascular disease. But, whilst the stimulation of angiogenesis may relieve microvascular disease, the bypass of occluded conduit vessels requires the formation of more substantial collateral vessels by the process of arteriogenesis. This chapter will review current understanding of the mechanisms controlling angiogenesis

and arteriogenesis; approaches that are, and could be pursued to induce vessel growth in peripheral vascular disease, as well as summarizing the current status of clinical trials.

### MECHANISMS OF VASCULAR GROWTH

Strategies currently being developed for the therapeutic induction of vessel growth have evolved, largely, from knowledge of the physiological mechanisms of developmental vascularisation. In development, blood vessels arise initially by the process of vasculogenesis during which precursor cells, known as angioblasts, differentiate into endothelial cells and organize into primitive vessels.<sup>1</sup> These vessels expand by angiogenesis, which includes both sprouting growth and non-sprouting remodelling.<sup>1</sup>

#### Vasculogenesis

The angioblasts that give rise to endothelial cells in the first stages of developmental vascularisation originate in the mesoderm under the influence of fibroblast growth factor-2 (FGF-2).<sup>2</sup> These differentiate into endothelial cells, which proliferate and aggregate into cords, and become lumenized

to form primitive vascular plexuses.<sup>1</sup> Signalling through vascular endothelial growth factor receptor-2 (VEGF-R2) is crucial for angioblast survival and establishment of these first vessels.<sup>3</sup>

Endothelial cell formation from precursor cells, and *in situ* differentiation into vessels, was thought to be confined to developmental vascularisation. However, it has now been shown that circulating endothelial progenitor cells (EPCs) exist in the adult and that they can contribute to vessel formation.<sup>4</sup> These cells originate in the bone marrow and express CD34 and VEGF-R2 as well as the orphan receptor AC133.<sup>5</sup> EPCs can incorporate into neovessels formed in healing wounds, ischaemic tissue and tumours.<sup>6</sup> The mechanisms controlling the incorporation of EPCs into neovessels are at present poorly defined although a number of growth factors, including VEGF, FGF2, granulocyte-macrophage colony stimulating factor (GM-CSF), angiopoietins and cytokines have all been shown to increase the mobilization of EPCs from bone marrow.<sup>7</sup> Crude cell fractions that include EPCs can be expanded *ex vivo* and transplanted into ischaemic tissue in animal models where they have been reported to incorporate into neovessels.<sup>4</sup> Importantly, in some situations neovessels comprising only EPC-derived cells were observed. Several studies have highlighted that the increase in the number of circulating progenitors, induced by cell transfusion or enhanced mobilization, can also enhance restoration and integrity of the endothelial lining, suppress neointimal formation, and increase blood flow to ischaemic sites.<sup>8</sup> Whilst it is possible that EPCs, or EPC-derived cells, can form vessels *in situ*, by a process similar to vasculogenesis, current thinking suggests that the principal role of vascular stem and progenitor cells is paracrine, that is, these cells promote proliferation and migration of existing endothelial cells, as well as produce

additional cytokines and chemokines to continue stem and progenitor mobilization, trafficking and adhesion.<sup>9</sup>

## Angiogenesis

Establishment of the vascular network in development, as well as new vessel formation in the adult, requires angiogenesis. The two processes of sprouting and non-sprouting angiogenesis are responsible for remodelling of the primitive vascular plexus into a complex functional network. In sprouting angiogenesis, endothelial cells are activated by growth factors to undergo migration, proliferation and morphogenesis into new vessels, and VEGF is the major physiological activator.

Ischaemia is the primary initiator of sprouting angiogenic growth. Low oxygen tension activates expression of a wide range of angiogenic factors including VEGF, VEGF receptors, angiopoietin-2 and platelet-derived growth factor (PDGF). Genes for these factors contain hypoxia responsive elements in their promoters and some, like VEGF, have been shown to be direct targets of the transcriptional regulator hypoxia inducible factor (HIF). HIF-1 is a heterodimer composed of HIF $\alpha$  and HIF $\beta$  subunits.<sup>10</sup> Under normoxic conditions HIF-1 $\alpha$  is held at low intracellular concentrations by proteosomal degradation. With decreased oxygen tension HIF-1 $\alpha$  becomes hydroxylated preventing its association with the von Hippel-Lindau ubiquitin ligase complex that is responsible for directing HIF-1 $\alpha$  for degradation.<sup>11</sup> Thus, HIF-1 $\alpha$  accumulates in the cell allowing it to activate transcription of hypoxia-inducible genes via the HIF $\alpha$ : $\beta$  dimer.

VEGF expressed in response to HIF is secreted by ischaemic cells and acts on endothelial cells in adjacent microvessels. In these previously quiescent microvessels, endothelial activation, proliferation and migration are

normally suppressed by signals from abluminal perivascular support cells; pericytes. This suppression needs to be relieved before angiogenesis can proceed.<sup>12</sup> The close interaction between endothelial cells and pericytes is promoted by the ligand angiopoietin-1, which is produced by the pericyte and acts on the endothelial receptor Tie2.<sup>13</sup> Disruption of this signalling interaction is likely to involve angiopoietin-2, another hypoxia-responsive molecule.<sup>14</sup> Angiopoietin-2 can act to inhibit angiopoietin-1-induced activation of Tie2.<sup>15</sup> Once released from the pro-stabilizing effects of pericytes, the endothelial cells are free to invade the perivascular space, aided by proteases that degrade extracellular matrix. Many metalloproteinases have been implicated in angiogenic sprouting, including matrix metalloproteinases 2, 3, 7 and 9 as well as other proteolytic enzymes such as urokinase-type plasminogen activator.<sup>16</sup> Migration of the activated endothelial cells is aided by plasma proteins that extravasate from the activated microvessels in response to the vasodilatory and pro-permeability effects of VEGF. This growth factor is a potent chemoattractant and mitogen for endothelial cells, and directs their migration and proliferation. Interestingly, *in vivo* endothelial cells in the developing vascular sprouts respond differentially to VEGF, with the cells at the tip migrating and those behind the tip proliferating.<sup>17</sup> Migration and proliferation give rise to endothelial cords that become lumenized, a process which is poorly understood, though is known to be enhanced by angiopoietin-1.<sup>18</sup>

### Neovessel maturation

Whether by vasculogenesis or angiogenesis, newly formed blood vessels are highly unstable, and are prone to haemorrhage, thrombosis and spontaneous regression in the absence of elevated growth factors.<sup>19</sup>

Such vessels are characteristically found in pathological vascularisation and their phenotype can directly contribute to the disease process. Newly formed primitive vascular channels are maintained by local high concentrations of VEGF, withdrawal of which leads to endothelial apoptosis and neovessel regression.<sup>20</sup> Transformation to a functional vessel requires interaction of endothelial cells in the nascent vessel with pericytes, which originate as mesenchymal cells that are recruited to the developing vessel and differentiate into pericytes on contact with the endothelium.<sup>21</sup> Proliferation and migration of partially or fully differentiated pericytes along established microvessels also contributes to mural cell acquisition by sprouting neovessels, and sprouts can themselves recruit mesenchymal cells.<sup>22</sup> Migration and proliferation of pericytes is regulated mainly by platelet-derived growth factor- $\beta$  (PDGF $\beta$ ) secreted by endothelial cells. Interaction between mesenchymal cells and endothelial cells in a developing vessel produces phenotypic changes in both cell types. The mesenchymal cell is directed toward a pericyte or smooth muscle phenotype and the endothelial cell adopts the phenotype required for formation of a stabilized microvessel.<sup>1</sup> Pericytes supply anti-apoptotic ligands, including angiopoietin-1,<sup>23</sup> to underlying endothelial cells allowing neovessels to survive the decrease in VEGF concentrations that occur as the ischaemia is relieved by increased perfusion. In addition, pericytes suppress endothelial proliferation and migration, and increase deposition of the perivascular basement membrane, all of which contribute to switching the fragile nascent vessel into a quiescent functional microvessel.<sup>24</sup> Transforming growth factor- $\beta$ , produced by proteolytic cleavage from a precursor form as a result of endothelial:pericyte interaction,<sup>25</sup> has a central role in these effects.

### Microvascular network maturation

Maturation of vascular channels into functional vessels is accompanied by maturation of the neovessel network. This involves optimization of the new vessel configuration, density, branching pattern and vessel hierarchy. Spatial distributions of angiogenic initiators, like VEGF, have a major influence on the direction of the initial branches. There are six members of the VEGF family and VEGF-A is expressed as a number of alternatively spliced variants; in humans these are mainly forms with 121, 165, 189 and 206 amino acids.<sup>26</sup> VEGF165, 189 and 206 possess heparin-binding domains that allow these forms to interact with the extracellular matrix. The ability of VEGF isoforms to be retained by the matrix is important in regulating the spatial organization of vessel branching.<sup>27</sup>

Patterning also occurs through selective loss of certain vessels by regression. Another major determinant of network maturation is the branching and 'splitting' of vessels by non-sprouting angiogenesis. This occurs by the process of intussusception in which vessel lumens are internally divided by insertion, and subsequent growth and stabilization, of transcapillary tissue pillars.<sup>28</sup> The mechanism of intussusception and factors that regulate it are poorly understood, though the Tie receptors are known to have a role.<sup>29</sup>

### Arteriogenesis

Further expansion and muscularization of vessels occurs by the process of arteriogenesis; the development of large calibre collateral arteries from a pre-existing network, in response to occlusive disease. This involves recruitment of additional mural cells and their proliferation, as well as expansion of the abluminal extracellular matrix. Whilst

angiogenesis is driven by ischaemia, the initiator of arteriogenesis is increased fluid shear stress, which acts directly upon gene expression involved in the endothelial cell cycle.<sup>30</sup> PDGF $\beta$  with its effects on smooth muscle cell recruitment and proliferation, and TGF $\beta$ , a known regulator of vascular extracellular matrix synthesis, are likely to be key regulators.

Arteriogenesis of collateral vessels has been demonstrated in a number of animal models following the occlusion of major vessels.<sup>31</sup> In humans, well-developed collateral vessels that bypass occluded arteries have been found frequently and those patients with the best developed collaterals often have minimal symptoms.<sup>32</sup> Arteriogenesis of collaterals in response to the occlusion of primary supply vessels occurs in two phases. An initial increase in the lumen size occurs within a few days and this is followed by a slower remodelling of smooth muscle cell and extracellular matrix cover.<sup>31</sup> The early phase of this adaptive arteriogenesis is associated with inflammation. There is monocyte attachment to endothelium secondary to release of monocyte chemoattractant protein-1 (MCP-1), GM-CSF and stromal-cell-derived factor-1 (SDF-1), which recruit CD14<sup>+</sup> monocytes to the activated endothelial cell surface as well as extravasation and accumulation in the adventitia and perivascular space, with mast cells and T lymphocytes.<sup>33</sup> Monocytes have a critical role in adaptive arteriogenesis as experimental suppression of monocyte numbers decreases arteriogenesis.<sup>34</sup> These cells provide growth factors to stimulate vessel enlargement and proteases that can act on the extracellular matrix to accommodate increased vessel size. Changes to the wall of the vessel involve remodelling of the media, with increased turnover of medial smooth muscle cells and a shift towards a synthetic phenotype, assuming a contractile phenotype after enlargement of arterial diameter.<sup>33</sup>

A new internal elastic lamina is established and vessel wall thickening results from increased extracellular matrix deposition.

## THERAPEUTIC INDUCTION OF VASCULAR GROWTH

Most studies on the therapeutic induction of vessel growth at a pre-clinical level, and all clinical trials, have focused on angiogenesis. Clinical trials aimed at relieving peripheral vascular disease by therapeutic angiogenesis have had limited success. This is perhaps not surprising given the very limited ability of angiogenic growth to compensate for the loss of conductance vessels. It is now being generally recognised that revascularisation in peripheral vascular disease, as in coronary heart disease, would be best achieved by the therapeutic activation of collateral arteriogenesis. Nevertheless, the ability to activate angiogenesis therapeutically would be valuable where significant microvascular disease exists. In addition, the early work on therapeutic angiogenesis has provided data and approaches that may be valuable in future studies aimed at the activation of arteriogenesis.

### **Delivery of molecular activators of vascular growth**

Induction of angiogenesis in the appropriate ischaemic areas and in future local arteriogenesis at suitable sites for collateral development, requires activating agents to be delivered in a manner that ensures controllable local activity and minimizes systemic side effects. Growth factors are readily degraded and if administered systemically would have to be used at high concentrations in order to ensure enough active growth factor reached the appropriate site. There are risks associated with non-local delivery, for example, systemically delivered

VEGF produces severe hypotension in animal models.<sup>35</sup> In addition to localization, activators must be present for sufficient time to induce optimal vascular growth.

The two principal methods used to deliver angiogenic activators in pre-clinical studies as well as clinical trials have been as recombinant proteins or as the genes that encode these proteins. Activators can be delivered locally via intramuscular catheters, direct injection into the muscle or use of coated stents. An important consideration in the use of peptide growth factors is ensuring sufficient longevity of the molecules at the desired site. Where recombinant proteins are injected this would necessitate multiple injections during the course of treatment. An alternative strategy is the use of local reservoirs of recombinant protein, such as biodegradable microspheres.<sup>36</sup> A major limitation to the use of recombinant protein, however, is the expense and difficulty in obtaining large enough quantities of appropriate purity, especially when cocktails of growth factors are required.

Delivery of angiogenic factors by gene transfer has significant advantages over the administration of recombinant protein. It is relatively easy to produce high purity DNA in large quantities and the transfected genes remain active over a period of several days to several weeks. In contrast to gene therapy aimed at correcting genetic diseases, gene transfer as a means of providing short term local expression of therapeutic proteins has been successful. Surprisingly, small amounts of DNA plasmid vectors can be taken up by muscle cells *in vivo* and are reported to result in significant gene expression in humans.<sup>37</sup> Improvements in transfer efficiency have been sought by the use of liposomal carriers and viral vectors. Adenovirus is the most common viral vector used for the delivery of angiogenic genes, and since genes transferred in this way do not integrate into



chromosomes of transduced cells, transient expression is provided.

There have been reports of an inflammatory reaction to adenoviral vectors in human trials, but no long term safety problems at doses appropriate for angiogenic therapy. Second generation adenoviral vectors with deletions of E1 and E4 regions have better transfection efficiency and elicit a decreased inflammatory response<sup>38</sup> and further improved adenoviral vectors can be expected.<sup>39</sup> The adeno-associated viruses (AAV) offer an alternative viral means for gene delivery. AAV efficiently transduce skeletal muscle and vasculature.<sup>40</sup> However, along with retroviruses and lentiviruses, AAV integrate into the recipient genome requiring the development of regulatory systems if they are to provide controllable expression of vascular growth genes. As with recombinant protein, local delivery of genes can be accomplished by direct intramuscular injection, implantation of coated stents or catheters. It may also be possible to utilize tissue-specific endothelial surface molecules for targeting vectors to particular vascular beds. Implantation of cells transfected *ex vivo* offers an additional route of local delivery.

### Angiogenic activators

Perhaps the simplest approach to activating angiogenesis is the administration of a soluble angiogenic activator. VEGF is relatively specific for endothelial cells and physiologically relevant. Although VEGF-A, -B, -C, -D and -E, as well as the VEGF-R1 ligand placental growth factor, have all been shown to activate angiogenesis when administered in animal models, most studies have concentrated on VEGF-A. Administration of VEGF alone results in a high percentage of malformed capillaries in animal models.<sup>41</sup> This growth factor also induces vessel permeability resulting in local hypotension and oedema.<sup>35</sup>

Neovessels induced by VEGF are transient, with regression occurring on growth factor withdrawal.<sup>42</sup> These data indicate formation of a sustained microvessel network may require relatively long term exposure to the angiogenic initiator.

The fibroblast growth factors have also been examined as potential therapeutic agents to induce angiogenesis in clinical trials. There are 23 members of the FGF family and FGF-2 and FGF-4 have been used in clinical trials. FGF-1, -2, -4 and -9 are highly mitogenic for endothelial cells, although these growth factors are also active on non-endothelial cells.<sup>43</sup> Another growth factor that induces angiogenesis and is in early trials is hepatocyte growth factor; again its effects are not confined to endothelial cells.<sup>44</sup>

With the recognition that physiological angiogenesis requires a spatially and temporally co-ordinated repertoire of signals, attempts have been made to improve capillary formation by providing cocktails of growth factors. Indeed combination of VEGF with the pro-stabilizing Tie2 agonist angiopoietin-1 in a mouse model does produce microvessels with increased lumen size, less thrombosis and increased perfusion compared with VEGF alone.<sup>18</sup> These vessels are also less permeable than those formed in response to VEGF alone.<sup>45</sup> Another approach aimed at providing a more physiological range of angiogenic factors is the targeting of HIF. Expression of a form of HIF-1 $\alpha$  that is resistant to oxygen-induced degradation in mouse skin led to up-regulation of HIF-sensitive angiogenic genes and the stimulation of microvessel formation.<sup>46</sup> Again the vessels produced were not associated with oedema. The cell permeable peptide, PR39, inhibits proteosomal degradation and can stabilize HIF-1 $\alpha$ .<sup>47</sup> PR39 stimulates angiogenesis in mouse heart, although further studies are required to determine its specificity.<sup>47</sup>

Pre-clinical and early clinical studies have shown that angiogenesis can be induced *in vivo* by a variety of approaches. The challenge is to devise a means to stimulate the conversion of these neovessels into optimally organized, persistent and functional microvascular networks.

### Arteriogenic activators

Little is known about the molecular mechanisms of arteriogenesis. In contrast to the ischaemic tissue microenvironment in which angiogenesis occurs, collateral arteriogenesis in the limb takes place in normoxic conditions.<sup>48</sup> In adaptive arteriogenesis studied in animal models, the biochemical effects of the increased flow that the collaterals experience as a result of occlusion of conductance vessels plays a major role. These effects include increased wall shear stress as well as tangential and axial stresses. Increased shear can up-regulate vascular cell adhesion molecule-1 and intracellular adhesion molecule-1, as well as MCP-1 which contributes to monocyte recruitment.<sup>49</sup> Growth factors are undoubtedly involved in adaptive arteriogenesis, but again more work is required to identify the key factors and their roles. In animal models FGF-1 and FGF-2 were found to be unchanged during adaptive arteriogenesis, although there was a transient increase in expression of FGF-receptor-1.<sup>50</sup>

TGF $\beta$  is increased during collateral development and can enhance arteriogenesis in animal models. Several factors have been found to enhance arteriogenesis when administered to animals, including FGF-2, VEGF, placental growth factor, angiopoietin-1 and MCP-1, although the exact mechanisms of action remain undefined.<sup>31</sup> Many appear to have indirect actions, for example, VEGF and placental growth factor infusions are likely to enhance arteriogenesis via their monocyte chemoattractive activity. Given

the great potential of therapeutic induction of collateral arteriogenesis for the treatment of peripheral vascular disease, it is important that a better understanding of the molecular mechanisms be gained. Identification of key regulators that can induce or enhance arteriogenesis of collaterals is a priority.

### Clinical trials for angiogenic therapy of peripheral vascular disease

There have been a number of phase 2 and 3 clinical trials aimed at relieving peripheral vascular disease by angiogenic therapy. The Therapeutic Angiogenesis with Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) study used single or repeated doses of recombinant FGF-2 delivered by arterial puncture and cross-over catheter in patients with intermittent claudication. Patients receiving a single FGF-2 dose showed a significant improvement in peak walking time at 90 days.<sup>51</sup> In the Regional Angiogenesis with Vascular Endothelial Growth Factor (RAVE) study, VEGF121 gene transfer by adenovirus was utilized but failed to produce a significant improvement in peak walking time at 12 weeks.<sup>52</sup> In contrast, in a different study adenoviral delivered VEGF165 given during angioplasty did produce an increased angiographically-assessed vascularity at 3 months.<sup>53</sup> The Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis (VIVA) trial failed to show a difference between the treatment and placebo groups for the primary endpoint of walking time.<sup>54</sup> The TALISMAN collaborators evaluated a plasmid-based angiogenic gene delivery system for the local expression of FGF-1 in patients with non-healing ulcers who were not suitable for invasive re-vascularisation. Whilst there was no difference observed in the primary endpoint of complete ulcer healing, there was a reduced risk of major amputation.<sup>55</sup> Initial

reports from the ongoing Bone Marrow Outcome Trial in Critical Limb Ischemia (BONMOT-CLI), show promise for the intramuscular injection of autologous bone marrow stem cells into ischaemic limbs, with significant improvements in Rutherford categories and a trend against major limb amputation.<sup>56</sup>

A meta-analysis of 5 randomised controlled trials investigating the role of gene therapy as an option for the treatment of peripheral vascular disease concluded that the current literature does not demonstrate a clinical benefit for patients with peripheral vascular disease.<sup>57</sup> Although these trials have met with limited success, together with phase 1 studies and earlier small trials, they demonstrate the feasibility and safety of molecular approaches to therapeutic modulation of vascular growth. The trials have also been valuable in aiding development of techniques for delivering therapeutic agents, as well as helping clinicians refine aspects of trial design for future clinical work on arteriogenesis and angiogenesis.

The realization that therapeutic induction of collateralization by arteriogenesis would be most appropriate for occlusive disease, whilst angiogenic therapy would benefit patients with microvascular defects, should help improve selection of the most appropriate populations for use in future trials. Clear clinical end-points are required in such work. Where angiogenesis is the aim, establishment of optimal treatment modalities will depend on further pre-clinical work focused on determining ways to establish mature, correctly patterned vascular networks. This may involve defined cocktails of stimulators, or activation of transcriptional factors triggering coordinated expression of stimulators. In both cases distinct spatial and temporal expression patterns are likely to be required.

## CONCLUSIONS

The prospects for a molecular approach to stimulate vascular growth as a means of relieving tissue ischaemia in peripheral vascular disease are promising. Early clinical work, together with a better understanding of vascular growth mechanisms, has allowed identification of the key areas in which progress is required in order to bring therapeutic vascular growth to the clinic. Yet Isner predicted in therapeutic angiogenesis 'a new frontier for vascular therapy' in 1996.<sup>58</sup> That today the underlying cellular mechanisms and processes continue to be elucidated is testament to the complexity of this area of vascular medicine. Bypassing the occluded conductance vessels is now recognised to require collateral growth by arteriogenesis, rather than angiogenesis. In comparison to angiogenesis our understanding of arteriogenesis remains rudimentary. Significant work is needed therefore to understand the mechanisms regulating physiological arteriogenesis as well as adaptive arteriogenesis, and to identify key molecular regulators. Activation of angiogenic growth will be valuable where microvascular disease is prevalent. Indeed, situations in which activation of arteriogenesis to restore conductance level flow together with activation of angiogenesis to relieve microvascular defects can be envisaged. It is clear that optimum microvascular growth will require correctly patterned, functional and persistent mature microvessel networks. Further work on the basic biology of angiogenesis is needed to determine the best means of inducing this therapeutically.

## REFERENCES


1. Risau W. Mechanisms of angiogenesis. *Nature* 1997; **386**: 671–4.
2. Poole TJ, Finkelstein EB, Cox CM. The role of FGF and VEGF in

- angioblast induction and migration during vascular development. *Dev Dyn* 2001; **220**: 1–17.
3. Shalaby F, Rossant T, Yamaguchi T, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature* 1995; **376**: 62–6.
  4. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997; **275**: 964–7.
  5. Gehling UM, Ergün S, Schumacher U, et al. *In vitro* differentiation of endothelial cells from AC133-positive progenitor cells. *Blood* 2000; **95**: 3106–12.
  6. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularisation. *Circ Res* 1999; **85**: 221–8.
  7. Junhui Z, Xingxiang W, Guosheng F, et al. Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. *Resp Med* 2008; **102**: 1073–9.
  8. Awaf O, Dedkov EI, Jiao C, et al. Differential healing activities of CD34+ and CD14+ endothelial cells progenitors. *Arterioscler Thromb Vasc Biol* 2006; **26**: 758–64.
  9. Gnecci M, Zhang Z, Ni A, Dzau V. Paracrine mechanisms in adult stem cell signalling and therapy. *Circ Res* 2008; **103**: 1204–19.
  10. Semenza GL. Transcriptional regulation by hypoxia-inducible factor 1. *Trends Cardiovasc Med* 1996; **6**: 151–7.
  11. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. *Nat Med* 2003; **9**: 677–84.
  12. Darland DC, D'Amore PA. Cell-cell interactions in vascular development. *Curr Top Dev Biol* 2001; **52**: 107–49.
  13. Suri C, Jones PE, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. *Cell* 1996; **87**: 1171–80.
  14. Oh H, Takagi H, Suzuma K, et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. *J Biol Chem* 1999; **274**: 15732–9.
  15. Maisonpierre PC, Suri C, Jones PE, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. *Science* 1997; **277**: 55–60.
  16. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nat Med* 2000; **6**: 389–95.
  17. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J Cell Biol* 2003; **161**: 1164–77.
  18. Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-2, modulate VEGF-induced postnatal neovascularisation. *Circ Res* 1998; **83**: 233–40.
  19. Benjamin LE, Golijanin A, Itin A, et al. Selective ablation of immature blood vessels in established human tumours follows vascular endothelial growth factor withdrawal. *J Clin Inv* 1999; **103**: 159–65.
  20. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. *Nat Med* 1995; **1**: 1024–8.

21. Beck L, D'Amore PA. Vascular development: cellular and molecular regulation. *FASEB J* 1997; **11**: 365–73.
22. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. *Development* 1998; **125**: 1591–8.
23. Kim I, Kim HG, So JN, et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. *Circ Res* 2000; **86**: 24–9.
24. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. *Cardiovasc Res* 1996; **32**: 687–98.
25. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor beta is produced by co-cultures of endothelial cells and pericytes. *Proc Natl Acad Sci USA* 1998; **86**: 4544–8.
26. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med* 2003; **9**: 669–76.
27. Ruhrberg C, Gerhardt H, Golding M, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. *Genes Dev* 2002; **16**: 2687–98.
28. Djonov V, Schmid M, Tschanz A, Burri PH. Intussusceptive angiogenesis: its role in embryonic vascular network formation. *Circ Res* 2000; **86**: 286–92.
29. Patan S. TIE1 and TIE2 receptor tyrokinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. *Microvasc Res* 1998; **56**: 1–21.
30. Schierling W, Troidl K, Troidl C, et al. The role of angiogenic growth factors in arteriogenesis. *J Vasc Res* 2009; **46**: 365–74.
31. Schaper W, Scholz D. Factors regulating arteriogenesis. *Arterioscler* 2003; **23**: 1143–51.
32. Maseri A, Araujo L, Finocchiaro ML. in 'Collateral Circulation: Heart, Brain, Kidney, Limbs' (Schaper W & Schaper J eds.): 381–402. Kluwer Academic, Boston, MA, 1993.
33. Sneider EB, Nowicki PT, Messina LM. Regenerative medicine in the treatment of peripheral arterial disease. *J Cell Biochem* 2009; **108**: 753–61.
34. Heil M, Ziegelhoeffer, Pipp F, et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. *Am J Heart Circ Physiol* 2002; **283**: H2411–9.
35. Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. *J Surg Res* 1996; **63**: 77–82.
36. Arras M, Mollnau H, Strasser R. The delivery of angiogenic factors to the heart by microsphere therapy. *Nat Biotech* 1998; **16**: 159–62.
37. Tripathy SK, Svensson EC, Black HB, et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. *Proc Natl Acad Sci USA* 1996; **93**: 10876–80.
38. Qian HS, Channon K, Nepliouva V, et al. Improved adenoviral vector for vascular gene therapy: beneficial effects on vascular function and inflammation. *Circ Res* 2001; **88**: 911–7.

39. Maione D, Della Rocca C, Giannetti P, et al. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes pre-existing immunity to adenovirus. *Proc Natl Acad Sci USA* 2001; **98**: 5986–91.
40. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? *Mol Med Today* 2000; **6**: 433–40.
41. Drake CJ, Little CD. Exogenous vascular endothelial growth factor induces malformed and hyperperfused vessels during embryonic neovascularisation. *Proc Natl Acad Sci USA* 1995; **92**: 7657–61.
42. Dor Y, Djonov V, Abramovitch, et al. Conditional switching of VEGF provides new insights into adult neovascularisation and pro-angiogenic therapy. *EMBO J.* 2002; **21**: 1939–47.
43. Javerzat S, Auguste P, Bikflavi A. The role of fibroblast growth factors in vascular development. *Trends Mol Med* 2002; **8**: 483–9.
44. Morishita R, Nakamura S, Hayashi S, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. *Hypertension* 1999; **33**: 1379–84.
45. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. *Science* 1999; **286**: 2511–4.
46. Elson DA, Thurston G, Huang LE, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. *Genes Dev* 2001; **15**: 2520–32.
47. Li J, Post M, Volk R, et al. PR39, a peptide regulator of angiogenesis. *Nat Med* 2000; **6**: 49–55.
48. Ito WD, Arras M, Scholz D, et al. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. *Am J Phys* 1997; **273**: H1255–65.
49. Walpoda PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered stress. *Arterioscler Thromb Vasc Biol* 1995; **15**: 2–10.
50. Deindl E, Hoefler IE, Fernandez B, et al. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis. *Circ Res* 2003; **92**: 561–8.
51. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. *Lancet* 2002; **359**: 2053–8.
52. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, doubleblind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. *Circ* 2003; **108**: 1933–8.
53. Makinen K, Manninen H, Hedman M. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. *Mol Ther* 2002; **6**: 127–33.

54. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. *Circ* 2003; **107**: 1359–65.
55. Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. *Mol Ther* 2008; **16**: 972–8.
56. Amann B, Lüdermann, Rückert R, et al. Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONE Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI). *Vasa* 2008; **37**: 319–25.
57. Ghosh R, Walsh SR, Tang TY et al. Gene therapy as a novel therapeutic option in the treatment of peripheral vascular disease: systematic review and meta-analysis. *International J Clin Prac* 2008; **62**: 1383–90.
58. Isner JM. Therapeutic angiogenesis: a new frontier for vascular therapy. *Vasc Med* 1996; **1**: 79–87.



Cover diagram by David Heinrich of the *Medical Illustration and Media Unit, Flinders Medical Centre*. (See chapter 18)

## MECHANISMS OF VASCULAR DISEASE

Edited by Robert Fitridge and Matthew Thompson

**Chapter 1:** Endothelium **Chapter 2:** Vascular smooth muscle structure and function **Chapter 3:** Atherosclerosis **Chapter 4:** Mechanisms of plaque rupture **Chapter 5:** Current and emerging therapies in atheroprotection **Chapter 6:** Molecular approaches to revascularisation in peripheral vascular disease **Chapter 7:** Biology of restenosis and targets for intervention **Chapter 8:** Vascular arterial haemodynamics **Chapter 9:** Physiological haemostasis **Chapter 10:** Hypercoagulable states **Chapter 11:** Platelets in the pathogenesis of vascular disease and their role as a therapeutic target **Chapter 12:** Pathogenesis of aortic aneurysms **Chapter 13:** Pharmacological treatment of aneurysms **Chapter 14:** Aortic dissection and connective tissue disorders **Chapter 15:** Biomarkers in vascular disease **Chapter 16:** Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon **Chapter 17:** SIRS, sepsis and multiorgan failure **Chapter 18:** Pathophysiology of reperfusion injury **Chapter 19:** Compartment syndrome **Chapter 20:** Pathophysiology of pain **Chapter 21:** Postamputation pain **Chapter 22:** Treatment of neuropathic pain **Chapter 23:** Principles of wound healing **Chapter 24:** Pathophysiology and principles of varicose veins **Chapter 25:** Chronic venous insufficiency and leg ulceration: Principles and vascular biology **Chapter 26:** Pathophysiology and principles of management of the diabetic foot **Chapter 27:** Lymphoedema – Principles, genetics and pathophysiology **Chapter 28:** Graft materials past and future **Chapter 29:** Pathophysiology of vascular graft infections



BARR SMITH PRESS

An imprint of  
The University of Adelaide Press